Cell Signalling, Injury and Repair Group, Institute of Cellular Medicine, Newcastle University, Framlington Place, Newcastle-upon-Tyne NE2 4HH, United Kingdom.
J Biol Chem. 2010 Jul 16;285(29):22414-25. doi: 10.1074/jbc.M110.120121. Epub 2010 May 12.
The protein kinase C (PKC) signaling pathway is a major regulator of cellular functions and is implicated in pathologies involving extracellular matrix remodeling. Inflammatory joint disease is characterized by excessive extracellular matrix catabolism, and here we assess the role of PKC in the induction of the collagenases, matrix metalloproteinase (MMP)-1 and MMP-13, in human chondrocytes by the potent cytokine stimulus interleukin-1 (IL-1) in combination with oncostatin M (OSM). IL-1 + OSM-stimulated collagenolysis and gelatinase activity were ameliorated by pharmacological PKC inhibition in bovine cartilage, as was collagenase gene induction in human chondrocytes. Small interfering RNA-mediated silencing of PKC gene expression showed that both novel (nPKC delta, nPKC eta) and atypical (aPKC zeta, aPKC iota) isoforms were involved in collagenase induction by IL-1. However, MMP1 and MMP13 induction by IL-1 + OSM was inhibited only by aPKC silencing, suggesting that only atypical isoforms play a significant role in complex inflammatory milieus. Silencing of either aPKC led to diminished IL-1 + OSM-dependent extracellular signal-regulated kinase (ERK) and signal transducer and activator of transcription (STAT) 3 phosphorylation, and c-fos expression. STAT3 gene silencing or ERK pathway inhibition also resulted in loss of IL-1 + OSM-stimulated c-fos and collagenase expression. Silencing of c-fos and c-jun expression was sufficient to abrogate IL-1 + OSM-stimulated collagenase gene induction, and overexpression of both c-fos and c-jun was sufficient to drive transcription from the MMP1 promoter in the absence of a stimulus. Our data identify atypical PKC isozymes as STAT and ERK activators that mediate c-fos and collagenase expression during IL-1 + OSM synergy in human chondrocytes. aPKCs may constitute potential therapeutic targets for inflammatory joint diseases involving increased collagenase expression.
蛋白激酶 C(PKC)信号通路是细胞功能的主要调节剂,与涉及细胞外基质重塑的病理学有关。炎症性关节疾病的特征是细胞外基质的过度分解代谢,在这里,我们评估了 PKC 在人软骨细胞中通过强力细胞因子刺激白细胞介素-1(IL-1)与肿瘤坏死因子(OSM)的协同作用诱导胶原酶、基质金属蛋白酶(MMP)-1 和 MMP-13 中的作用。在牛软骨中,通过药理学 PKC 抑制,IL-1+OSM 刺激的胶原溶解和明胶酶活性以及人软骨细胞中的胶原酶基因诱导均得到改善。PKC 基因表达的小干扰 RNA 介导的沉默表明,新型(nPKC delta、nPKC eta)和非典型(aPKC zeta、aPKC iota)同工型均参与了 IL-1 诱导的胶原酶诱导。然而,只有 aPKC 的沉默抑制了 MMP1 和 MMP13 由 IL-1+OSM 诱导,这表明只有非典型同工型在复杂的炎症环境中发挥重要作用。沉默任何一种 aPKC 都会导致 IL-1+OSM 依赖性细胞外信号调节激酶(ERK)和信号转导和转录激活因子(STAT)3 磷酸化和 c-fos 表达减少。STAT3 基因沉默或 ERK 途径抑制也导致 IL-1+OSM 刺激的 c-fos 和胶原酶表达丧失。沉默 c-fos 和 c-jun 的表达足以阻断 IL-1+OSM 刺激的胶原酶基因诱导,并且在没有刺激的情况下,c-fos 和 c-jun 的过表达足以驱动 MMP1 启动子的转录。我们的数据表明,非典型 PKC 同工型是 STAT 和 ERK 的激活剂,可介导人软骨细胞中 IL-1+OSM 协同作用下的 c-fos 和胶原酶表达。aPKC 可能成为涉及胶原酶表达增加的炎症性关节疾病的潜在治疗靶点。